- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
FDA approves Rituxan for lymphoma maintenance
The US Food and Drug Administration has approved the use of the anti-CD20 monoclonal antibody Rituxan (rituximab) in patients with advanced stage follicular lymphoma who have previously had a response to first-line or induction therapy that included Rituxan and chemotherapy.
Approval was given based on the results from the so-called PRIMA (Primary Rituxan and Maintenance) study.